公司概述
Sotera Health Company operates within the healthcare sector, specifically focusing on the diagnostics and research industry by providing sterilization solutions, laboratory testing, and advisory services across the United States, Canada, Europe, and international markets. The company executes its business strategy through three distinct segments: Sterigenics, Nordion, and Nelson Labs, with the Sterigenics segment offering outsourced services to healthcare clients. In terms of scale, Sotera Health Company holds a market capitalization of $4.33 billion and generates annual revenue of $1.16 billion while employing approximately 3,000 staff members. These valuation and revenue figures indicate that the company occupies a significant position within its niche, leveraging a substantial operational footprint to serve a global clientele with specialized medical technologies and testing capabilities.
财务健康
The company reported a trailing twelve-month revenue of $1.16 billion with a net income of $77.94 million and an EBITDA of $553.36 million, revealing a substantial gap between total revenue and net income that highlights the magnitude of operating expenses, interest costs, and tax obligations inherent in its cost structure. The entity generated free cash flow of $236.80 million, which signifies a robust capacity to fund capital expenditures, service debt obligations, and potentially pursue strategic acquisitions without relying heavily on external financing. Margin analysis shows a gross margin of 55.5%, an operating margin of 35.8%, and a profit margin of 6.7%; the high gross and operating margins suggest efficient production and service delivery, while the lower profit margin reflects the impact of significant overhead and interest expenses. On the balance sheet, the company holds $344.90 million in cash against $2.28 billion in debt, resulting in a debt-to-equity ratio of 375.56, which characterizes a highly leveraged financial position rather than a conservative one. Despite the leverage, the current ratio stands at 2.46, indicating that the company possesses ample liquid assets relative to its short-term liabilities and maintains strong short-term liquidity. Return on equity is 15.4% and return on assets is 8.2%, metrics that reveal management's effectiveness in generating returns from shareholders' capital and the total asset base respectively, despite the elevated debt levels.
估值评估
Sotera Health Company trades with a trailing twelve-month P/E ratio of 56.44 and a forward P/E ratio of 14.56, implying that the market currently prices in a dramatic expansion of earnings or that future earnings are expected to surge significantly to justify the high current multiple. The price-to-book ratio is 7.15, indicating that the market values the company's equity at a substantial premium over its net book value, likely reflecting intangible assets, brand strength, or growth prospects not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 3.72 and an EV/EBITDA of 11.32, which suggest the market is willing to pay a premium for revenue and earnings relative to sales and cash flow generation. The stock's 52-week trading range spans from a low of $9.53 to a high of $19.85, providing context for price volatility and historical performance boundaries. The beta value of 1.88 indicates that the stock exhibits high price volatility, moving with significantly greater intensity than the broader market, which amplifies both potential gains and losses during market fluctuations.
Growth & Income
Revenue growth year-over-year is 4.6%, while earnings growth year-over-year is 175.4%, demonstrating that earnings are growing at a rate far exceeding revenue expansion, which often points to significant cost efficiencies, one-time gains, or a substantial change in the earnings mix. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm currently retains all earnings to reinvest into the business, debt reduction, or strategic initiatives rather than distributing cash to shareholders. This reinvestment strategy supports the company's long-term growth trajectory in the diagnostics and sterilization sectors rather than providing immediate income to investors. Overall, the growth and income profile is characterized by explosive earnings acceleration driven by high growth rates and a zero-dividend policy focused on capital allocation for future expansion.